Express Scripts (NASDAQ:ESRX) was upgraded by stock analysts at Sanford C. Bernstein from an “underperform” rating to a “market perform” rating in a report issued on Wednesday, The Fly reports.

Other analysts also recently issued research reports about the company. TheStreet raised Express Scripts from a “c+” rating to a “b-” rating in a research note on Monday. Zacks Investment Research raised Express Scripts from a “hold” rating to a “buy” rating and set a $64.00 price objective on the stock in a research note on Monday, October 16th. ValuEngine raised Express Scripts from a “hold” rating to a “buy” rating in a research note on Monday, October 2nd. Jefferies Group set a $72.00 price objective on Express Scripts and gave the stock a “buy” rating in a research note on Tuesday, August 29th. Finally, Deutsche Bank initiated coverage on Express Scripts in a research note on Monday. They issued a “buy” rating and a $75.00 price objective on the stock. Six equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $70.67.

Shares of Express Scripts (NASDAQ:ESRX) opened at $67.84 on Wednesday. The company has a quick ratio of 0.61, a current ratio of 0.73 and a debt-to-equity ratio of 0.86. Express Scripts has a 12 month low of $55.80 and a 12 month high of $77.25. The stock has a market capitalization of $38,603.98, a P/E ratio of 9.96, a price-to-earnings-growth ratio of 1.01 and a beta of 0.88.

Express Scripts (NASDAQ:ESRX) last released its quarterly earnings data on Tuesday, October 24th. The company reported $1.90 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $1.90. Express Scripts had a return on equity of 25.46% and a net margin of 3.64%. The business had revenue of $24.68 billion for the quarter, compared to the consensus estimate of $25.68 billion. During the same quarter in the previous year, the company posted $1.74 EPS. The company’s revenue was down 2.9% compared to the same quarter last year. sell-side analysts expect that Express Scripts will post 7.01 earnings per share for the current year.

In other Express Scripts news, CEO Timothy C. Wentworth acquired 8,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 31st. The stock was bought at an average price of $61.13 per share, for a total transaction of $489,040.00. Following the acquisition, the chief executive officer now directly owns 98,628 shares in the company, valued at $6,029,129.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Phyllis S. Anderson sold 578 shares of the business’s stock in a transaction on Friday, September 8th. The shares were sold at an average price of $63.13, for a total value of $36,489.14. Following the transaction, the vice president now owns 10,530 shares of the company’s stock, valued at approximately $664,758.90. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 5,121 shares of company stock valued at $325,920. 0.68% of the stock is owned by company insiders.

Hedge funds have recently modified their holdings of the business. Harel Insurance Investments & Financial Services Ltd. increased its position in Express Scripts by 20.9% during the 2nd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,503 shares of the company’s stock valued at $114,000 after buying an additional 260 shares in the last quarter. Burt Wealth Advisors increased its position in Express Scripts by 11.4% during the 2nd quarter. Burt Wealth Advisors now owns 1,696 shares of the company’s stock valued at $108,000 after buying an additional 174 shares in the last quarter. Independent Advisor Alliance acquired a new position in Express Scripts during the 4th quarter valued at about $124,000. Dubuque Bank & Trust Co. increased its position in Express Scripts by 53.1% during the 1st quarter. Dubuque Bank & Trust Co. now owns 1,753 shares of the company’s stock valued at $116,000 after buying an additional 608 shares in the last quarter. Finally, Capital Analysts LLC increased its position in Express Scripts by 15.2% during the 4th quarter. Capital Analysts LLC now owns 1,777 shares of the company’s stock valued at $122,000 after buying an additional 235 shares in the last quarter. Institutional investors and hedge funds own 88.44% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This report was first reported by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was stolen and reposted in violation of international copyright & trademark law. The original version of this report can be read at https://www.americanbankingnews.com/2017/12/06/express-scripts-esrx-upgraded-by-sanford-c-bernstein-to-market-perform.html.

About Express Scripts

Express Scripts, Inc is a pharmacy benefit management (PBM) company in North America, offering a range of services to its clients, which include health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans and government health programs. It operates in two segments: PBM and Emerging Markets (EM).

The Fly

Analyst Recommendations for Express Scripts (NASDAQ:ESRX)

Receive News & Ratings for Express Scripts Holding Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts Holding Company and related companies with MarketBeat.com's FREE daily email newsletter.